I placebo- kontrollerede studier var bosentan- relateret fald i hæmoglobinkoncentrationen ikke progressivt og stabiliseredes efter de første 4– 12 ugers behandling.
In placebo-controlled studies, bosentan-related decreases in haemoglobin concentration were not progressive, and stabilised after the first 4– 12 weeks of treatment.